Facebook
Twitter
Telegram
Report an ErrorRepare Therapeutics Balance Sheet 2011-2024 | RPTX
Annual Balance Sheet Repare Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-108 M | -154 M | -327 M | -322 M | -93.7 M | -10.7 M | - | - | - | - | - | - | - |
Long Term Debt |
1.01 M | 3.26 M | 5.59 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
2.4 M | 2.17 M | 1.72 M | 697 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 59.2 M | 145 M | 34.4 M | - | - | - | - | - | - | - |
Total Current Liabilities |
39.1 M | 78.6 M | 35.1 M | 11 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
41.8 M | 84.6 M | 80.3 M | 70.3 M | 149 M | 36.3 M | - | - | - | - | - | - | - |
Deferred Revenue |
10.2 M | 53.1 M | 11.9 M | 2.07 M | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-333 M | -239 M | -210 M | -103 M | -49.9 M | -22.7 M | - | - | - | - | - | - | - |
Total Assets |
254 M | 364 M | 369 M | 357 M | 103 M | 13.9 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
111 M | 160 M | 334 M | 326 M | 95 M | - | - | - | - | - | - | - | - |
Book Value |
212 M | 280 M | 288 M | 287 M | -46.1 M | -22.4 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
212 M | 280 M | 288 M | 287 M | -46.1 M | -22.4 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Repare Therapeutics
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
561 K | 1.01 M | 1.59 M | 2.23 M | 2.78 M | 3.26 M | 3.77 M | - | 5.15 M | 5.59 M | 5.62 M | 3.54 M | 3.24 M | 3.31 M | 3.31 M | 3.31 M | 3.31 M | 439 K | 439 K | 439 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
31.1 M | 41.8 M | 53 M | 56.2 M | 85.1 M | 84.6 M | 103 M | - | 78.5 M | 80.3 M | 77.4 M | 75.6 M | 71.4 M | 70.3 M | 70.3 M | 70.3 M | 70.3 M | 12.8 M | 12.8 M | 12.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
1.07 M | 10.2 M | 20.5 M | 24.4 M | 52.8 M | 53.1 M | 34.8 M | - | 11.9 M | 11.9 M | 8.92 M | 8.76 M | 2.08 M | 2.07 M | 2.07 M | 2.07 M | 2.07 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-320 M | -333 M | -305 M | -286 M | -274 M | -239 M | -208 M | - | -245 M | -210 M | -182 M | -151 M | -125 M | -103 M | -103 M | -103 M | -103 M | -49.9 M | -49.9 M | -49.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
263 M | 254 M | 286 M | 302 M | 336 M | 364 M | 409 M | - | 337 M | 369 M | 296 M | 321 M | 339 M | 357 M | 357 M | 357 M | 357 M | 103 M | 103 M | 103 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
103 M | 111 M | 107 M | 116 M | 121 M | 160 M | 155 M | - | 305 M | 334 M | 261 M | 294 M | 311 M | 326 M | 326 M | 326 M | 326 M | 94.8 M | 105 M | 94.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
232 M | 212 M | 233 M | 245 M | 251 M | 280 M | 306 M | - | 259 M | 288 M | 218 M | 245 M | 268 M | 287 M | 287 M | 287 M | 287 M | 89.9 M | 89.9 M | 89.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
232 M | 212 M | 233 M | 245 M | 251 M | 280 M | 306 M | 226 M | 259 M | 288 M | 218 M | 245 M | 268 M | 287 M | 287 M | 287 M | 287 M | -46.1 M | -46.1 M | -46.1 M | -27.2 M | -22.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency